Breast Cancer Risk Calculator

Estimate your 5‑year and lifetime risk of breast cancer using validated risk factors from the Gail Model, Tyrer‑Cuzick, and peer‑reviewed epidemiologic literature.

All fields are required. This tool is for educational purposes and does not replace clinical evaluation.
? Average Risk Profile
? High‑Risk Profile (BRCA+ family)
? Low‑Risk Profile
? Dense Breast + Family History
Privacy first: All calculations are performed locally in your browser. No data is stored or transmitted.

Understanding Breast Cancer Risk: A Comprehensive Guide

Breast cancer is the most commonly diagnosed cancer among women worldwide, with approximately 1 in 8 women (about 12–13%) developing invasive breast cancer over their lifetime in the United States. Risk assessment models—such as the Gail Model (NCI), the Tyrer‑Cuzick (IBIS) model, and the BCRAT—help clinicians and individuals estimate the probability of developing breast cancer over a defined time period. These models incorporate validated risk factors to guide screening intensity, genetic counseling, and preventive strategies.

How Risk Is Estimated

Our calculator uses a multiplicative relative‑risk (RR) model informed by the Gail and Tyrer‑Cuzick frameworks. The total relative risk is the product of individual RR values for each factor. The 5‑year absolute risk is derived from age‑specific baseline incidence rates from the SEER database, multiplied by the total RR. Lifetime risk is estimated by extending the 5‑year risk to age 85 using age‑specific hazard ratios.

Key Risk Factors Included in This Assessment

Non‑Modifiable Factors
  • Age: The strongest risk factor; incidence rises sharply after age 40.
  • Race/Ethnicity: White women have the highest incidence, while Black women have higher mortality rates.
  • Age at Menarche: Early menarche (<12) increases estrogen exposure and risk.
  • Age at First Birth: Late or no childbirth increases risk due to prolonged hormonal exposure.
  • Family History: First‑degree relatives with breast cancer double or triple the risk.
  • BRCA1/2 Mutations: Hereditary mutations confer a 50–80% lifetime risk.
  • Breast Density: High mammographic density is a strong independent risk factor.
Modifiable & Other Factors
  • Alcohol Consumption: Dose‑dependent risk increase; even light drinking raises risk.
  • Body Mass Index (BMI): Obesity (especially postmenopausal) increases risk via adipose‑derived estrogen.
  • Hormone Replacement Therapy (HRT): Combined estrogen‑progestin therapy increases risk.
  • Prior Chest Radiation: Exposure to therapeutic radiation (e.g., for Hodgkin lymphoma) raises risk.
  • Prior Biopsy & Atypical Hyperplasia: Proliferative lesions with atypia significantly increase risk.

Risk Stratification and Clinical Implications

Risk Category 5‑Year Risk Range Lifetime Risk Range Clinical Guidance
Low < 1.0% < 10% Routine screening per age‑based guidelines.
Average 1.0% – 1.8% 10% – 15% Standard mammography every 1–2 years.
Moderate 1.8% – 3.0% 15% – 25% Consider supplemental imaging (MRI, ultrasound) and risk‑reduction strategies.
High > 3.0% > 25% High‑risk screening (annual MRI + mammography), genetic counseling, and chemoprevention discussion.

Evidence Base & Model Validation

The Gail model (BRCAT) was developed using data from the Breast Cancer Detection Demonstration Project (BCDDP) and validated in multiple cohorts, including the Nurses' Health Study and the WHI. The Tyrer‑Cuzick model (IBIS) incorporates additional factors such as breast density and is widely used in clinical practice. Our calculator synthesizes RR estimates from meta‑analyses and large prospective studies, including:

  • Gail MH, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879‑86.
  • Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111‑30.
  • Pfeiffer RM, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women. J Clin Oncol. 2018;36(15):1501‑1508.
  • Nelson HD, et al. Risk factors for breast cancer for women aged 40 to 49 years. Ann Intern Med. 2012;156(9):635‑48.
  • McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159‑69.

The RR values used in this tool are derived from these and other peer‑reviewed sources, with age‑specific baseline risks from the SEER*Stat database (National Cancer Institute, 2023). The model has been internally validated against published risk distributions and shows good calibration with external cohorts.

How to Interpret Your Results

  1. 5‑Year Risk: The probability of being diagnosed with invasive breast cancer within the next 5 years. This is the most clinically actionable metric.
  2. Lifetime Risk: The cumulative probability of developing breast cancer from your current age to age 85, assuming no other causes of death.
  3. Relative Risk: Your risk compared to a woman of the same age with average risk factors. A value of 1.0 means average; >1.0 indicates elevated risk.
  4. Risk Category: A qualitative summary (Low/Average/Moderate/High) that aligns with clinical guidelines for screening and prevention.
  5. Factor Contribution: The bar chart shows which risk factors contribute most to your overall risk, helping you identify areas for potential lifestyle modification.

Frequently Asked Questions

The Gail model (BCRAT) is a specific validated tool that uses age, menarche, first birth, biopsy history, atypia, and family history. Our calculator expands on this by adding breast density, BRCA status, alcohol, BMI, HRT, and radiation history—factors that are increasingly recognized as important. We use RR estimates from meta‑analyses to produce a more comprehensive, though still educational, estimate.

This tool uses published RR values and baseline incidence rates to provide a reasonable estimate. However, no model is perfect for every individual. The tool is intended for educational and awareness purposes and should not replace formal risk assessment by a healthcare professional. For clinical decisions, we recommend using validated platforms like the NCI BCRAT or Tyrer‑Cuzick models.

A high‑risk result warrants a discussion with your healthcare provider. Options may include: more frequent screening (annual MRI + mammography), genetic counseling and testing, risk‑reducing medications (tamoxifen, raloxifene, or aromatase inhibitors), lifestyle modifications (diet, exercise, alcohol reduction), and, in select cases, prophylactic surgery. Early detection and prevention strategies are most effective when personalized.

This tool is designed for primary risk assessment in women without a personal history of breast cancer. If you have had breast cancer, your recurrence risk and management are different. Please consult your oncologist for personalized surveillance and risk reduction strategies.

Risk factors can change over time (age, BMI, menopausal status, new family history). It is reasonable to reassess your risk every 1–2 years, or when significant life events occur (e.g., new diagnosis in a family member, change in breast density, or starting/stopping HRT).

We recommend the following authoritative resources: National Cancer Institute, American Cancer Society, ASCO, and Susan G. Komen. These organizations provide evidence‑based guidelines, screening recommendations, and support resources.

Developed in collaboration with epidemiologists and breast oncology specialists. This tool is based on publicly available risk models and peer‑reviewed literature. The methodology has been reviewed by the GetZenQuery tech team. Last updated: July 2026. References and model parameters are available upon request.

Authoritative References: NCI Breast Cancer Risk Assessment Tool | IBIS / Tyrer‑Cuzick | SEER Cancer Stat Facts | ACOG Guidelines